contract_awardAwarded Wednesday, May 27, 2026Analyzed

USANTIBIOTICS LLC: $30.0M Department of Health and Human Services Contract

Neutral

Summary

A $30.0M delivery order for amoxicillin capsules was awarded to privately-held USANTIBIOTICS LLC by HHS/ASPR. Because the recipient is private, no public tickers are directly affected, but the contract signals continued government investment in antibiotic stockpiling for pandemic preparedness.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.Private company USANTIBIOTICS LLC received $30M for amoxicillin capsules, no public ticker exposure.
  • 2.The award signals ongoing government stockpiling of generic antibiotics, supporting the healthcare sector's preparedness subsector.
  • 3.No direct legislative authorizing bill identified; likely funded through HHS/ASPR base appropriations for the Strategic National Stockpile.

Market Implications

No immediate market impact because the recipient is private. The contract is small relative to the generic drug market. For context, the U.S. generic antibiotic market is worth billions annually, and a $30M order is negligible for large players. No stock price movement is expected from this award alone.

Full Analysis

1) This contract is a $30.0M delivery order to USANTIBIOTICS LLC for amoxicillin trihydrate oral capsules (500mg, 60- and 100-count), awarded by the Department of Health and Human Services through the Office of Assistant Secretary for Preparedness and Response. It runs from May 2026 to May 2027, indicating a one-year supply arrangement for a critical generic antibiotic. 2) USANTIBIOTICS LLC is not a publicly-traded entity or a recognized subsidiary of any public company. As a private firm, its financials and competitive position are opaque to public market investors. No tickers are mapped. 3) Related legislation includes S4551 (Restoring Overtime Pay Act of 2026, bearish, impact 2/10 on Healthcare), S4587 (Dietary Supplements Access Act, bullish, impact 3/10 on Healthcare), and S4634 (CONNECT Act, neutral, impact 2/10 on Healthcare). None of these bills directly authorize antibiotic procurement; the contract likely stems from BARDA or ASPR's Strategic National Stockpile (SNS) funding. 4) No publicly-traded subcontractors or suppliers are identified. Downstream beneficiaries could include generic drug manufacturers (e.g., $TEVA, $MYL) if they supply active pharmaceutical ingredients, but this is speculative. 5) Generic antibiotic contracts like this are routine SNS replenishments, typically stable and low-margin. They do not drive significant stock performance for large-cap pharma, but they reinforce the U.S. government's role as a reliable bulk buyer for essential medicines.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.

Contract Details

Recipient

USANTIBIOTICS LLC

Award Amount

$29,998,678

Awarding Agency

Department of Health and Human Services

Sub-Agency

Office of Assistant Secretary for Preparedness and Response

Contract Type

DELIVERY ORDER